Research ExplorerPublicationsNetwork Meta-analysis of the Benefit of Aspirin with Rivarox...

Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease

Standard

Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease. / Ambler, Graeme K; Nordanstig, Joakim; Behrendt, Christian-Alexander; Twine, Christopher P.

In: EUR J VASC ENDOVASC, Vol. 62, No. 4, 01.10.2021, p. 654-655.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Ambler, GK, Nordanstig, J, Behrendt, C-A & Twine, CP 2021, 'Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease', EUR J VASC ENDOVASC, vol. 62, no. 4, pp. 654-655. https://doi.org/10.1016/j.ejvs.2021.05.038

APA

Ambler, G. K., Nordanstig, J., Behrendt, C-A., & Twine, C. P. (2021). Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease. EUR J VASC ENDOVASC, 62(4), 654-655. https://doi.org/10.1016/j.ejvs.2021.05.038

Vancouver

Ambler GK, Nordanstig J, Behrendt C-A, Twine CP. Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease. EUR J VASC ENDOVASC. 2021 Oct 1;62(4):654-655. https://doi.org/10.1016/j.ejvs.2021.05.038

Bibtex

@article{ceb3b8cd810741cc86f53766e28210d5,
title = "Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease",
keywords = "Aged, Aspirin/adverse effects, Clopidogrel/adverse effects, Factor Xa Inhibitors/adverse effects, Female, Fibrinolytic Agents/adverse effects, Hemorrhage/chemically induced, Humans, Lower Extremity/blood supply, Male, Middle Aged, Network Meta-Analysis, Peripheral Arterial Disease/diagnosis, Platelet Aggregation Inhibitors/adverse effects, Randomized Controlled Trials as Topic, Rivaroxaban/adverse effects, Treatment Outcome",
author = "Ambler, {Graeme K} and Joakim Nordanstig and Christian-Alexander Behrendt and Twine, {Christopher P}",
year = "2021",
month = oct,
day = "1",
doi = "10.1016/j.ejvs.2021.05.038",
language = "English",
volume = "62",
pages = "654--655",
journal = "EUR J VASC ENDOVASC",
issn = "1078-5884",
publisher = "W.B. Saunders Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease

AU - Ambler, Graeme K

AU - Nordanstig, Joakim

AU - Behrendt, Christian-Alexander

AU - Twine, Christopher P

PY - 2021/10/1

Y1 - 2021/10/1

KW - Aged

KW - Aspirin/adverse effects

KW - Clopidogrel/adverse effects

KW - Factor Xa Inhibitors/adverse effects

KW - Female

KW - Fibrinolytic Agents/adverse effects

KW - Hemorrhage/chemically induced

KW - Humans

KW - Lower Extremity/blood supply

KW - Male

KW - Middle Aged

KW - Network Meta-Analysis

KW - Peripheral Arterial Disease/diagnosis

KW - Platelet Aggregation Inhibitors/adverse effects

KW - Randomized Controlled Trials as Topic

KW - Rivaroxaban/adverse effects

KW - Treatment Outcome

U2 - 10.1016/j.ejvs.2021.05.038

DO - 10.1016/j.ejvs.2021.05.038

M3 - Other (editorial matter etc.)

C2 - 34452837

VL - 62

SP - 654

EP - 655

JO - EUR J VASC ENDOVASC

JF - EUR J VASC ENDOVASC

SN - 1078-5884

IS - 4

ER -